Top line results for Redhill's triple antibiotic treatment for MAP

RedHill Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

For any interested or that have been following.

Here is what has been released so far:

/www.redhillbio.com/RedHill/Templates/showpage.asp?DBid=1&LNGid=1&TMid=178&Fid=1384&Pid=0&Iid=8178

Thanks to whomever posted the original link. I bought and sold RDHL when it was about 7.35 a share and sold at 11.20. I watched the trading action in Tel-Aviv after the trading halt and shorted the stock at the open at 10.43 on the NASDAQ. Bought the shares back at the 7.00 level. I told my brother-in-law but he always waits to buy and ended up losing a lot of money (on paper) through his own stupidity. Another one of their phase III tests comes out in September related to H-pylori. RDHL earnings date has not as yet been stated, I look to this as a bad sign the phase III results came out before their second quarter earnings came out. Not even made public knowledge was the test was done with all the subjects still on their drugs for crohn's or crohn's colitis. The test was not done with the subjects cold turkey off all crohn's drugs and only on the 3 antibiotics. The reason the stock went straight up then straight down was the 52 week remission results compared to the 26 week results. The test was poorly done at a great expense and the company didn't state the exact day the test results would be made public. The same with their second quarter earnings results. I emailed the company and told them RH 104 might be effective against lyme disease.

Any GI can already prescribe it. The dosage/abx are well documented. The backing of the study is of course beneficial though.